ACLY and metabolic dysfunction-associated steatotic liver disease: In Mendelian randomization studies, genetic variants that mimic the effect of ACLY inhibition were associated with reductions in serum biomarkers of cardiovascular risk such as triglycerides and LDL cholesterol, non-alcoholic fatty liver disease (NAFLD), body fat and type 2 diabetes (20, 21).